George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
To seek capital appreciation through investment in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis.
Find out MoreLondon South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I know that last statement appears to be big ramp but such development would only be a continuation of the current chart which more than doubled between jan 2012 and dec 2013 (it actually doubled earlier but went sideways for about 6 months). The logic below simply offers a reasonable scenario on how things might proceed. This could yet continue to double every 2 years.
..,The long term earnings per share growth for major biotechnology companies is an estimated 18%... http://www.frostrow.com/wp-content/uploads/2013/12/The-Biotech-Grth-Tst-Half-Year-Accounts-2013.pdf The above rate suggests EPS will double in just over 4 yrs. Note also that this is the just the projection for major companies and that BIOG uses it's expertise to select smaller companies too. Smaller companies could have yet higher growth rates! At some stage the PE might also increase to reflect the EPS growth. It's not inconceivable that this Trust could yet triple or more over the next 4 years...
Consider that 430 resistance well and truely broken :)
Me too. Money in here should have a decent upside whilst still being able to sleep at night. I am still in SUMM and waiting for a good exit point but as you say, finding the next gem takes time. SAR is my other Biotech which I am sure will come good one day but is woeful at this point in time. Good luck and enjoy letting someone else take the strain!
And off we go .....
More or less exactly the same for me. I am particularly bullish on Biotech as a whole, but do not have the knowledge or time to find and monitor the best investments in the sector. Past performance here is very strong, and see no reason why they won't continue this in the future. Takes away a lot of the stress too!
Exiting= exciting
Hi Dan. Yes, but I'm also hoping history repeats! According to the last half yearly report P/E ratios are similar to major pharmaceutical companies but the long term earnings per share growth is 3.6 times higher! I want to be in this sector but you really need to know what you are doing- I've learnt this the hard way. This trust takes away a lot the worry but still has exiting record and upside.
Aiming for your gains in 10 years? ;) But yeah.. Right on. Saying that, this is a true buy and hold - would be pretty confident not looking at this for 5 years and wouldn't have any worries along the way.
Just bought another tranche in here. The chart over the last few years shows a surge in H1. We've been testing resistance recently at around 430 and I fancy we're breaking through it. Let's hope history repeats in H1 2024!
Nobody talks.... :)
tend to let the trades and share price do the talking. GLA
Must be the quietest board I have ever seen.
That's the sort of thing that happens to me. Was going to buy in here but went for aas instead. I worked in the pharma industry for years and lost my job due to the decrease in profitable small molecules. Larger biotech molecules have a bright future IMO. Pfizer acquired Wyeth for their biotech portfolio while contracting their small molecule business. Eli Lilly have an increasing biotech portfolio. Bearing in mind it takes about 10 years to get a drug to market and the biotech industry is still relatively young I thing this will do well in the longer term.
They say shares is all about timing, well I bough some BIOG shares about a month ago, having been very impressed with their long term share performance. Unfortunatley they have gone down 9% since I bough them. Just wondered if anybody more experienced than me has any views on why the current dip ? Thanks.
BIOTECH GROWTH TRUST BEATS BENCHMARK Biotech Growth Trust outperformed its benchmark in the three months to the end of June. The trust's net asset value per share rose by 11.0% compared with a 7.6% rise in the NASDAQ Biotechnology Index measured in sterling terms. The company said the NAV performance was, in part, due to strong returns from portfolio holdings in Questcor Pharmaceuticals, following reports of strong sales of its multiple sclerosis treatment Acthar and also from Onyx Pharmaceuticals, following a positive vote from a US Food & Drug Administration Panel for the approval of its drug Carfilzomib for the treatment of advanced Myeloma. P.S. Here's a couple of links about SCLP, one of the hottest stocks at the moment: http://www.euroinvestor.com/community/discussionthread.aspx?threadid=256596 http://www.euroinvestor.com/community/discussionthread.aspx?threadid=253089
Looking at individual investment portfolios, the Biotech Growth trust was the quarter’s best performer in terms of both net asset value (NAV) and share price. Over the three months, its NAV rose 19.1% while share price was up 11.4% on a total return basis. Source: http://www.fundweb.co.uk/investment-trusts/news/trusts-ahead-of-open-ended-peers-despite-q2-underperformance/1053944.article
Valuation: Discount marginally below long-term averages The current low discount of 0.3% (three- and five-year averages are 6.1% and 6.4% respectively) is supported by sector fundamentals and, when compared with peers, BIOG’s performance record and clear discount maintenance policy
http://www.edisoninvestmentresearch.co.uk/researchreports/BIOG260712review.pdf
Hello............I'm new to this IT fund but believe it could be profitable, as past result seem to be strong. Any wiser heads that have an opinion.....would be glad to hear from you? PS........I'm not a prolific blogger so I'm not looking for an opportunity to spend all day in chit-chat.
Up 30% today huge potential for tomorrow 28 July 2011 ValiRx Plc ("ValiRx" or the "Company") Successful Progress in Preclinical Study of Lead Therapeutic Compound VAL201 in Collaboration with Oxford University VAL201 shown to prevent proliferative tissue growth in live studies with reduced side effects ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to report that a further late preclinical study into the development of one of its lead therapeutics, VAL201, carried out in collaboration with Oxford University, has firmly established a potentially important role for VAL201 in treating hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancer, among others. These conditions currently have high medical needs, This progress follows on from ValiRx's agreement with Oxford University, as announced on 14 April 2011, to accelerate the development of this lead therapeutic and to study VAL201's therapeutic potential for additional indications. In the studies thus far, VAL201 has been shown to prevent cancerous growth in live models, with two proliferative conditions and in a further three conditions in cancer cell lines. The response has been shown to be dose dependent. Furthermore, ValiRx is also pleased to note that those models treated with VAL201 remain fertile and produce normal offspring and, unlike many other traditional therapies, no serious side effects have so far been seen. In the models seen thus far, treatment with VAL201 potentially leaves other hormone induced activities working normally, therefore reducing side effects such as lowered sexual function and infertility. As such, VAL201 shows promise for superior therapeutics for hormone induced abnormal growth in a number of conditions. Following the successful completion of this study, both ValiRx and Oxford University now look forward to continuing the next stage of VAL201's preclinical programme to support the regulatory requirements prior to entering clinical trials. Dr Satu Vainikka, CEO, commented: "I am delighted with the progress we are seeing, both in terms of the development of VAL201 and the benefit of our collaboration with Oxford University. The market for treatments against hormone induced tumour growth and associated conditions is huge* and these conditions have significant unmet clinical need. I am very excited by the results of this first study and by the further potential markets and conditions that VAL201 and ValiRx Plc can address."
http://www.investegate.co.uk/Article.aspx?id=20100616150010PDAA0
Because it outperformed over the past 5 years and it has a holding in Gilead Sciences. Give up or persevere?